Daily Sepsis Research Analysis
Analyzed 13 papers and selected 3 impactful papers.
Summary
Analyzed 13 papers and selected 3 impactful articles.
Selected Articles
1. Phosphorylated toll-like receptor 4 defines a high-risk sepsis endotype.
In a prospective cohort of 100 sepsis patients, in vivo TLR4 activation measured by receptor phosphorylation was generally low but elevated in a subset. Higher activation at day 1 and day 4 independently predicted worse 30-day survival, defining a high-risk sepsis endotype and supporting biomarker-guided precision therapeutics.
Impact: This study quantifies in vivo TLR4 activation and directly links a phosphorylated TLR4 endotype to mortality, clarifying heterogeneous target engagement that may explain prior trial failures.
Clinical Implications: Phospho-TLR4 could stratify patients for future TLR4-targeted therapies and refine risk prognostication in sepsis, enabling enrichment strategies in biomarker-guided trials.
Key Findings
- Overall TLR4 activation was low (median <1 signal/cell) at day 1 and day 4.
- Elevated TLR4 activation predicted reduced 30-day survival at day 1 (HR 2.03, 95% CI 1.01–4.07; p=0.048) and day 4 (HR 2.77, 95% CI 1.14–6.73; p=0.025).
- Association remained significant after adjustment for SOFA, age, infection focus, and sex (multivariable p=0.006).
- Findings delineate a high-risk sepsis endotype defined by enhanced in vivo TLR4 phosphorylation.
Methodological Strengths
- Prospective sampling at two clinically relevant timepoints with validated proximity ligation assay for receptor phosphorylation.
- Robust survival analysis including multivariable Cox regression adjusting for key confounders.
Limitations
- Single-cohort observational design limits causal inference and external generalizability.
- Thresholds for 'elevated' phosphorylation and assay standardization across centers require validation.
Future Directions: Validate phospho-TLR4 cut-offs across cohorts and integrate into biomarker-enriched RCTs of TLR4 inhibitors; assess longitudinal dynamics and treatment responsiveness.
BACKGROUND: Sepsis is a life-threatening condition characterized by a dysregulated immune response to infection. Toll-like receptor 4 plays a central role in pathogen recognition and inflammatory signalling and has been considered a key driver of sepsis pathophysiology. Pharmacological inhibition of this receptor showed beneficial effects in experimental models but failed in clinical trials. We therefore aimed to quantify in vivo activation of Toll-like receptor 4 in patients with sepsis and to determine its association with 30-day survival. METHODS: Peripheral blood mononuclear cells were obtained from 100 patients with sepsis enrolled in the SepsisDataNet.NRW cohort. Samples were collected on day 1 (within 36 h after diagnosis) and day 4. Activation of TLR4 was quantified by measuring receptor phosphorylation using a validated proximity ligation assay. Survival analyses were performed using Kaplan-Meier curves and Cox proportional hazards regression models to assess the association between receptor activation and 30-day mortality. RESULTS: Overall activation of TLR4 was low, with median values below one signal per cell at both day 1 and day 4. Despite the generally low levels, a subgroup of patients showed increased receptor activation. Higher activation was associated with significantly reduced 30-day survival. Patients with elevated activation had a higher risk of death both at day 1 (HR 2.03, 95% CI 1.01-4.07, p = 0.048) and day 4 (HR 2.77, 95% CI 1.14-6.73, p = 0.025). This association remained significant after adjustment for SOFA score at admission, age, infection focus and sex in multivariable Cox regression analysis (p = 0.006). CONCLUSIONS: In vivo activation of TLR4 is not uniformly present in patients with sepsis but occurs only in a subset of individuals. In those patients, increased activation is strongly associated with mortality. These findings suggest the presence of a distinct high-risk sepsis endotype characterized by enhanced receptor activation. This may help explain the failure of previous clinical trials of TLR4 inhibitors and supports the concept of biomarker-guided precision medicine approaches in sepsis. TRIAL REGISTRATION: German Clinical Trials Register (DRKS), DRKS00018871, retrospectively registered on 14 November 2019.
2. Targeted silencing of CLYBL with platelet-mimetic siRNA nanoparticles drives itaconate-mediated macrophage reprogramming and protects against sepsis-triggered lung cell death.
In a CLP mouse model, CLYBL was upregulated in macrophages and lung tissue. Platelet-mimetic PEVs@PLGA nanoparticles delivering siRNA against CLYBL boosted itaconate, restrained M1 polarization, preserved alveolar epithelium, and improved repair with minimal toxicity, nominating CLYBL as a metabolic checkpoint and therapeutic target.
Impact: Reveals CLYBL as a previously unrecognized metabolic checkpoint and demonstrates a translational nanoparticle strategy to reprogram macrophage metabolism and protect the lung in sepsis.
Clinical Implications: Although preclinical, targeted delivery of siRNA to modulate macrophage immunometabolism could inform future therapies for sepsis-induced lung injury and guide biomarker-driven patient selection.
Key Findings
- CLYBL expression was markedly upregulated in lung tissue and peritoneal macrophages in CLP mice.
- Platelet-mimetic PEVs@PLGA nanoparticles achieved efficient in vitro and in vivo delivery and robust CLYBL knockdown.
- CLYBL silencing increased itaconate, limited M1 macrophage polarization, preserved alveolar epithelial integrity, and reduced cell death.
- Transcriptomics showed broad immunometabolic remodeling consistent with enhanced resolution of inflammation.
- Biosafety assessments indicated negligible systemic toxicity.
Methodological Strengths
- Integrated in vivo CLP model, in vitro validation, and transcriptomic profiling.
- Biomimetic targeted delivery platform with demonstrated biosafety.
Limitations
- Findings are limited to murine CLP models; human relevance and inter-species translation remain uncertain.
- Long-term efficacy, dosing windows, and off-target effects of siRNA nanoparticles were not fully characterized.
Future Directions: Evaluate dose–response and timing, test in large animals, define pharmacokinetics and durability, and explore combination with standard sepsis care.
Excessive inflammation and metabolic dysregulation fuel alveolar cell death in sepsis-induced lung injury, yet effective molecular interventions are lacking. We identify citrate lyase beta-like (CLYBL) as a previously unrecognized metabolic driver of macrophage-mediated tissue damage. In a murine cecal ligation and puncture model, CLYBL was strongly upregulated in lung tissue and peritoneal macrophages. To therapeutically target this pathway, we engineered platelet-derived extracellular vesicle-coated poly(lactic-co-glycolic acid) nanoparticles (PEVs@PLGA) encapsulating CLYBL-specific small interfering RNA. This platelet-mimetic system enabled efficient, biocompatible delivery of siRNA and robust CLYBL knockdown both in vitro and in vivo. CLYBL silencing triggered accumulation of the anti-inflammatory metabolite itaconate, limited M1 macrophage polarization, and preserved alveolar epithelial integrity, thereby reducing cell death and improving pulmonary repair. Transcriptomic analysis revealed broad immunometabolic remodeling consistent with enhanced resolution of inflammation. Biosafety evaluation confirmed negligible systemic toxicity. These findings uncover CLYBL as a critical metabolic checkpoint linking macrophage activation to alveolar cell death and highlight platelet-mimetic siRNA nanoparticles as a potent therapeutic strategy. Our work provides a mechanistic and translational framework for targeting macrophage immunometabolism to prevent fatal organ damage during sepsis.PEVs@PLGA@si-CLYBL promote itaconate accumulation, induce immune cell functional remodeling, and facilitate lung epithelial repair, offering a novel therapeutic approach for sepsis-induced lung injury (Created with BioRender.com).
3. Kushenol E alleviates sepsis-associated cognitive dysfunction via microglial indoleamine 2,3-dioxygenase 1 inhibition.
In CLP mice, kushenol E preserved cognition and hippocampal structure, reduced neuroinflammation and oxidative stress, and limited kynurenine accumulation. Mechanistically, it directly inhibited microglial IDO1 catalytic activity without changing expression, and myeloid IDO1 overexpression attenuated the protective effect, supporting target engagement.
Impact: Establishes microglial IDO1 activity as a druggable driver of SAE and identifies kushenol E as a lead compound with in vivo target validation and functional rescue.
Clinical Implications: While preclinical, targeting the kynurenine pathway via microglial IDO1 may offer a path to treat cognitive sequelae in sepsis survivors and justify medicinal chemistry optimization of kushenol E.
Key Findings
- CLP induced cognitive impairment, neuronal loss, neuroinflammation, oxidative stress, and marked microglial IDO1 upregulation.
- Kushenol E preserved cognition, hippocampal integrity, and synapses, while suppressing neuroinflammation and limiting neurotoxic kynurenine accumulation.
- Kushenol E inhibited IDO1 catalytic activity without altering IDO1 transcript or protein levels in microglia.
- AAV9-mediated myeloid IDO1 overexpression attenuated kushenol E’s protective effects, supporting target engagement.
Methodological Strengths
- Comprehensive in vivo phenotyping (behavior, histology, biochemistry) with LC-MS/MS metabolite profiling.
- Target validation including direct enzyme activity inhibition and in vivo rescue via myeloid IDO1 overexpression.
Limitations
- Preclinical mouse study; species differences and pharmacokinetics of kushenol E remain undefined.
- Use of only male mice and potential behavioral confounders (e.g., sedation) were not fully addressed.
Future Directions: Medicinal chemistry optimization for potency/brain penetration, evaluation in female and aged models, PK/PD and safety profiling, and testing in larger animals.
BACKGROUND: Sepsis-associated encephalopathy (SAE) affects up to 70% of septic patients, but lacks specific therapeutic interventions. Indoleamine 2,3-dioxygenase 1 (IDO1) catalyzes tryptophan degradation via the kynurenine pathway, producing neurotoxic metabolites that drive neuroinflammation. PURPOSE: This study investigates whether kushenol E, a prenylated flavonoid from Sophora flavescens, mitigates SAE by inhibiting microglial IDO1. METHODS: Sepsis was induced by cecal ligation and puncture (CLP) in male C57BL/6J mice. Cognitive function was assessed by the novel object recognition test and the Morris water maze. Neuronal injury, neuroinflammation, and oxidative stress were evaluated by histology and biochemical assays. IDO1 expression was quantified by quantitative PCR and Western blot, and kynurenine pathway metabolites were profiled by LC-MS/MS. Kushenol E inhibition of murine IDO1 was verified in IFN-γ-stimulated BV-2 microglia. AAV9-mediated F4/80⁺ myeloid-cell-targeted IDO1 overexpression was used as an in vivo rescue strategy. RESULTS: CLP induced cognitive impairment, neuronal loss, neuroinflammation, and oxidative stress, accompanied by marked microglial IDO1 upregulation. Kushenol E preserved cognitive function, hippocampal integrity, and synaptic architecture; suppressed neuroinflammation; and limited neurotoxic kynurenine accumulation. Mechanistically, kushenol E inhibited IDO1 catalytic activity without altering its transcript or protein levels. In IFN-γ-stimulated BV-2 microglia, kushenol E suppressed kynurenine production in a concentration-dependent manner (IC CONCLUSION: Kushenol E mitigates SAE primarily by inhibiting microglial IDO1 catalytic activity, thereby limiting neurotoxic kynurenine production. These findings nominate microglial IDO1 as a therapeutic target for SAE and support kushenol E as a lead compound for the management of cognitive sequelae in sepsis survivors.